Krystal Biotech experienced an 8% drop in stock price to $312.37, despite reporting solid Q1 2026 earnings with revenue of $116.4 million and earnings per share of $1.91. Although the company showcased strong profits and healthy margins, the decline reflected a reset of investor expectations rather than a collapse in its earnings story. Analysts remain divided, with some seeing it as a potential bargain based on its high margins and growth prospects from its lead gene therapy, VYJUVEK, while others express concern over revenue reliability due to reimbursement issues and increasing operational costs.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-stock-price-drops-as-premium-expectatio
